<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LEUPROLIDE ACETATE-   
			 </strong><br>Sun Pharma Global FZE<br></p></div>
<h1>Leuprolide Acetate Injection</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin releasing hormone (GnRH or LH-RH). The analog possesses greater potency than the natural hormone. The chemical name is 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide acetate (salt) with the following structural formula:</p>
<br><div class="Figure"><img alt="leuprolide-structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3b01473-30c7-4945-bd60-2484221aaaad&amp;name=leuprolide-structure.jpg"></div>
<br><p>Leuprolide acetate injection is a sterile, aqueous solution intended for subcutaneous injection. It is available in a 2.8 mL multiple-dose vial containing leuprolide acetate [leuprorelin Ph Eur] (5 mg/mL), sodium chloride, USP (6.3 mg/mL) for tonicity adjustment, benzyl alcohol, NF as a preservative (9 mg/mL), and water for injection, USP. The pH may have been adjusted with sodium hydroxide, NF and/or glacial acetic acid, USP.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Leuprolide acetate, an LH-RH agonist, acts as a potent inhibitor of gonadotropin secretion when given continuously and in therapeutic doses. Animal and human studies indicate that following an initial stimulation of gonadotropins, chronic administration of leuprolide acetate results in suppression of ovarian and testicular steroidogenesis. This effect is reversible upon discontinuation of drug therapy. Administration of leuprolide acetate has resulted in inhibition of the growth of certain hormone dependent tumors (prostatic tumors in Noble and Dunning male rats and DMBA-induced mammary tumors in female rats) as well as <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of the reproductive organs.</p>
<br><p>In humans, subcutaneous administration of single daily doses of leuprolide acetate results in an initial increase in circulating levels of luteinizing hormone (LH) and follicle stimulating hormone (FSH), leading to a transient increase in levels of the gonadal steroids (testosterone and dihydrotestosterone in males, and estrone and estradiol in pre-menopausal females). However, continuous daily administration of leuprolide acetate results in decreased levels of LH and FSH. In males, testosterone is reduced to castrate levels. In pre-menopausal females, estrogens are reduced to post-menopausal levels. These decreases occur within two to four weeks after initiation of treatment, and castrate levels of testosterone in prostatic cancer patients have been demonstrated for periods of up to five years.</p>
<br><p>Leuprolide acetate is not active when given orally.</p>
<br><span><a name="s2.1"></a></span><span><a name="section-3.1"></a></span><p>Pharmacokinetics</p>
<span><a name="s2.1.1"></a></span><span><a name="section-3.1.1"></a></span><p>Absorption </p>
<p>Bioavailability by subcutaneous administration is comparable to that by intravenous administration.</p>
<br><span><a name="s2.1.2"></a></span><span><a name="section-3.1.2"></a></span><p>Distribution </p>
<p>The mean steady-state volume of distribution of leuprolide following intravenous bolus administration to healthy male volunteers was 27 L. <span class="Italics">In vitro</span> binding to human plasma proteins ranged from 43% to 49%.</p>
<br><span><a name="s2.1.3"></a></span><span><a name="section-3.1.3"></a></span><p>Metabolism </p>
<p>In healthy male volunteers, a 1 mg bolus of leuprolide administered intravenously revealed that the mean systemic clearance was 7.6 L/h, with a terminal elimination half-life of approximately 3 hours based on a two compartment model. In rats and dogs, administration of <span class="Sup">14</span>C-labeled leuprolide was shown to be metabolized to smaller inactive peptides, a pentapeptide (Metabolite I), tripeptides (Metabolites II and III) and a dipeptide (Metabolite IV). These fragments may be further catabolized.</p>
<br><p>The major metabolite (M-I) plasma concentrations measured in 5 prostate cancer patients reached maximum concentration 2 to 6 hours after dosing and were approximately 6% of the peak parent drug concentration. One week after dosing, mean plasma M-I concentrations were approximately 20% of mean leuprolide concentrations.</p>
<br><span><a name="s2.1.4"></a></span><span><a name="section-3.1.4"></a></span><p>Excretion </p>
<p>Following administration of LUPRON DEPOT* 3.75 mg to 3 patients, less than 5% of the dose was recovered as parent and M-I metabolite in the urine.</p>
<br><span><a name="s2.2"></a></span><span><a name="section-3.1.5"></a></span><p>Special Populations </p>
<p>The pharmacokinetics of the drug in hepatically and renally impaired patients has not been determined. </p>
<br><span><a name="s2.3"></a></span><span><a name="section-3.1.6"></a></span><p>Drug Interactions </p>
<p>No pharmacokinetic-based drug-drug interaction studies have been conducted with leuprolide acetate. However, because leuprolide acetate is a peptide that is primarily degraded by peptidase and not by cytochrome P-450 enzymes as noted in specific studies, and the drug is only about 46% bound to plasma proteins, drug interactions would not be expected to occur. </p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_13"></a><a name="section-3"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">In a controlled study comparing leuprolide acetate injection 1 mg/day given subcutaneously to DES (diethylstilbestrol), 3 mg/day, the survival rate for the two groups was comparable after two years of treatment. The objective response to treatment was also similar for the two groups.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_3"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Leuprolide acetate injection is indicated in the palliative treatment of advanced prostatic cancer.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<ol class="Arabic">
<li>Leuprolide acetate injection is contraindicated in patients known to be hypersensitive to GnRH, GnRH agonist analogs or any of the excipients in leuprolide acetate injection: Reports of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to GnRH agonist analogs have been reported in the medical literature.  </li>
<li>Leuprolide acetate injection is contraindicated in women who are or may become pregnant while receiving the drug. Leuprolide acetate injection may cause fetal harm when administered to a pregnant woman. Therefore, the possibility exists that <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span> may occur if the drug is administered during pregnancy. If this drug is administered during pregnancy or if the patient becomes pregnant while taking leuprolide acetate injection, the patient should be apprised of the potential hazard to the fetus.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Section_5"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Initially, leuprolide acetate injection, like other LH-RH agonists, causes increases in serum levels of testosterone. Transient worsening of symptoms, or the occurrence of additional signs and symptoms of prostate cancer, may occasionally develop during the first few weeks of leuprolide acetate injection treatment. A small number of patients may experience a temporary increase in <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, which can be managed symptomatically. As with other LH-RH agonists, isolated cases of ureteral obstruction and <span class="product-label-link" type="condition" conceptid="4322945" conceptname="Spinal cord compression">spinal cord compression</span> have been observed, which may contribute to <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> with or without fatal complications.</p>
<br><p>Safe use of leuprolide acetate in pregnancy has not been established clinically. Before starting treatment with leuprolide acetate injection, pregnancy must be excluded (see <a href="#Section_4">CONTRAINDICATIONS</a> section). </p>
<br><p>Periodic monitoring of serum testosterone and prostate-specific antigen (PSA) levels is recommended, especially if the anticipated clinical or biochemical response to treatment has not been achieved. It should be noted that results of testosterone determinations are dependent on assay methodology. It is advisable to be aware of the type and precision of the assay methodology to make appropriate clinical and therapeutic decisions.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Section_6"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Patients with metastatic vertebral lesions and/or with <span class="product-label-link" type="condition" conceptid="194406" conceptname="Urinary tract obstruction">urinary tract obstruction</span> should be closely observed during the first few weeks of therapy (see <a href="#Section_5">WARNINGS</a> and  <a href="#Section_7">ADVERSE REACTIONS</a> sections). Patients with known allergies to benzyl alcohol, an ingredient of the drug's vehicle, may present symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, usually local, in the form of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> and <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> at the injection site.</p>
<br><p><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and an increased risk of developing <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> have been reported in men receiving GnRH agonists. <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> may represent development of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or worsening of glycemic control in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Monitor blood glucose and/or <span class="product-label-link" type="condition" conceptid="4123836" conceptname="Glycosylated hemoglobin">glycosylated hemoglobin</span> (HbA1c) periodically in patients receiving a GnRH agonist and manage with current practice for treatment of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. </p>
<br><p>Increased risk of developing <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4317150" conceptname="Sudden cardiac death">sudden cardiac death</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> has been reported in association with use of GnRH agonists in men. The risk appears low based on the reported odds ratios, and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients receiving a GnRH agonist should be monitored for symptoms and signs suggestive of development of cardiovascular disease and be managed according to current clinical practice.</p>
<br><p><span class="Bold"><span class="Italics">Effect on QT/QTc Interval</span></span></p>
<p>Androgen deprivation therapy may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, frequent electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_6.2"></a><a name="section-7.1"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">See <a href="#Section_15">INFORMATION FOR PATIENTS</a> which appears after the <a href="#Section_14">REFERENCE</a> section.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="Section_6.3"></a><a name="section-7.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Response to leuprolide acetate should be monitored by measuring serum levels of testosterone and prostate-specific antigen (PSA). In the majority of patients, testosterone levels increased above baseline during the first week, declining thereafter to baseline levels or below by the end of the second week of treatment. Castrate levels were reached within two to four weeks and once attained were maintained for as long as drug administration continued.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_6.4"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">See <a href="#Section_2">CLINICAL PHARMACOLOGY</a>,  Pharmacokinetics section.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="Section_6.5"></a><a name="section-7.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Administration of leuprolide acetate in therapeutic doses results in suppression of the pituitary-gonadal system. Normal function is usually restored within 4 to 12 weeks after treatment is discontinued.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_6.6"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Two-year carcinogenicity studies were conducted in rats and mice. In rats, a dose-related increase of benign pituitary <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and benign <span class="product-label-link" type="condition" conceptid="437251" conceptname="Benign neoplasm of pituitary gland and craniopharyngeal duct">pituitary adenomas</span> was noted at 24 months when the drug was administered subcutaneously at high daily doses (0.6 to 4 mg/kg). There was a significant but not dose-related increase of pancreatic islet-cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in females and of testicular interstitial cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in males (highest incidence in the low dose group). In mice no pituitary abnormalities were observed at a dose as high as 60 mg/kg for two years. Patients have been treated with leuprolide acetate for up to three years with doses as high as 10 mg/day and for two years with doses as high as 20 mg/day without demonstrable pituitary abnormalities.</p>
<br><p>Mutagenicity studies have been performed with leuprolide acetate using bacterial and mammalian systems. These studies provided no evidence of a mutagenic potential.</p>
<br><p>Clinical and pharmacologic studies in adults (≥ 18 years) with leuprolide acetate and similar analogs have shown full reversibility of fertility suppression when the drug is discontinued after continuous administration for periods of up to 24 weeks. However, no clinical studies have been conducted with leuprolide acetate to assess the reversibility of fertility suppression.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_6.7"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">Teratogenic Effects</p>
<span><a name="s7.6.1.1"></a></span><span><a name="section-8.6.1.1"></a></span><p><span class="Italics">Pregnancy Category X</span></p>
<p>(see <a href="#Section_4">CONTRAINDICATIONS</a> and <a href="#Section_5">WARNINGS</a> sections).</p>
<p>When administered on day 6 of pregnancy at test dosages of 0.00024, 0.0024, and 0.024 mg/kg (1/600 to 1/6 the human dose) to rabbits, leuprolide acetate injection produced a dose-related increase in major fetal abnormalities. Similar studies in rats failed to demonstrate an increase in major <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> throughout gestation. There was increased fetal mortality and decreased fetal weights with the two higher doses of leuprolide acetate injection in rabbits and with the highest dose in rats. The effects on fetal mortality are expected consequences of the alterations in hormonal levels brought about by this drug.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_6.9"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether leuprolide acetate is excreted in human milk. Leuprolide acetate injection should not be used by nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_6.10"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">See labeling for leuprolide acetate injection for Pediatric Use for the safety and effectiveness in children with central <span class="product-label-link" type="condition" conceptid="4267558" conceptname="Precocious puberty">precocious puberty</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_6.11"></a><a name="section-7.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">In the clinical trials for leuprolide acetate injection, the majority (69%) of subjects studied were at least 65 years of age. Therefore, the labeling reflects the pharmacokinetics, efficacy and safety of leuprolide acetate injection in this population.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_7"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Clinical Trials</p>
<p>In the majority of patients testosterone levels increased above baseline during the first week, declining thereafter to baseline levels or below by the end of the second week of treatment. This transient increase was occasionally associated with a temporary worsening of signs and symptoms, usually manifested by an increase in <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span> (see <a href="#Section_5">WARNINGS</a> section). In a few cases a temporary worsening of existing <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> and <span class="product-label-link" type="condition" conceptid="194406" conceptname="Urinary tract obstruction">urinary tract obstruction</span> occurred during the first week. Temporary <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> of the lower limbs have been reported in a few cases.</p>
<br><p>Potential exacerbations of signs and symptoms during the first few weeks of treatment is a concern in patients with vertebral <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> and/or urinary obstruction which, if aggravated, may lead to neurological problems or increase the obstruction.</p>
<br><p>In a comparative trial of leuprolide acetate versus DES, in 5% or more of the patients receiving either drug, the following adverse reactions were reported to have a possible or probable relationship to drug as ascribed by the treating physician. Often, causality is difficult to assess in patients with metastatic prostate cancer. Reactions considered not drug related are excluded.</p>
<br><br><table border="0" cellpadding="0" cellspacing="0" width="86%">
<tfoot><tr><td colspan="0" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Physiologic effect of decreased testosterone.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top"><span><a name="t1"></a></span></td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Leuprolide Acetate<br>(N=98)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">DES<br>(N=101)</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top"></td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold">Number of Reports</span><span class="Bold"></span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Cardiovascular System<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span><br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  ECG changes/<span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span><br>
</td>
<td class="Rrule" align="center" valign="top">19<br>
</td>
<td class="Rrule" align="center" valign="top">22<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  High blood pressure<br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  Murmur<br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span><br>
</td>
<td class="Rrule" align="center" valign="top">12<br>
</td>
<td class="Rrule" align="center" valign="top">30<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span>/<span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span><br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">10<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Gastrointestinal System<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span><br>
</td>
<td class="Rrule" align="center" valign="top">6<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span><br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
<td class="Rrule" align="center" valign="top">9<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span><br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
<td class="Rrule" align="center" valign="top">17<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Endocrine System<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">
<span><a name="footnote-reference-1"></a>  </span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>Decreased testicular size<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
<td class="Rrule" align="center" valign="top">11<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<a href="#footnote-1" class="Sup">*</a><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span>/<span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span><br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
<td class="Rrule" align="center" valign="top">63<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  <a href="#footnote-1" class="Sup">*</a><span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot flashes</span><br>
</td>
<td class="Rrule" align="center" valign="top">55<br>
</td>
<td class="Rrule" align="center" valign="top">12<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  <a href="#footnote-1" class="Sup">*</a><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span><br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">12<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Hemic and Lymphatic System<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span><br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Musculoskeletal System<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Bone pain</span><br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span><br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">9<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Central/Peripheral Nervous System<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>/<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span><br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  General <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span><br>
</td>
<td class="Rrule" align="center" valign="top">13<br>
</td>
<td class="Rrule" align="center" valign="top">13<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>/<span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorders</span><br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Respiratory System<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span><br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  <span class="product-label-link" type="condition" conceptid="4220211" conceptname="Congestion of nasal sinus">Sinus congestion</span><br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
<td class="Rrule" align="center" valign="top">6<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Integumentary System<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span><br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Urogenital System<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  Frequency/urgency<br>
</td>
<td class="Rrule" align="center" valign="top">6<br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span><br>
</td>
<td class="Rrule" align="center" valign="top">6<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span><br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Miscellaneous<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="justify" valign="top">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span><br>
</td>
<td class="Rrule" align="center" valign="top">10<br>
</td>
<td class="Rrule" align="center" valign="top">10<br>
</td>
</tr>
</tbody>
</table>
<br><p>In this same study, the following adverse reactions were reported in less than 5% of the patients on leuprolide acetate injection.</p>
<br><p>Cardiovascular System - Angina, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>, Pulmonary emboli; Gastrointestinal System - <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disturbance</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">Peptic ulcer</span>, <span class="product-label-link" type="condition" conceptid="4216644" conceptname="Rectal polyp">Rectal polyps</span>; Endocrine System - Libido decrease, Thyroid enlargement; Musculoskeletal System - <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Joint pain</span>; Central/Peripheral Nervous System - <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span>, Memory disorder, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Mood swings</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>/<span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">blackouts</span>, Taste disorders; Respiratory System - <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>, <span class="product-label-link" type="condition" conceptid="4291941" conceptname="Pleural friction rub">Pleural rub</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">Pulmonary fibrosis</span>; Integumentary System - Carcinoma of skin/ear, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Hair loss</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span>, Local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span>, <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">Skin lesions</span>; Urogenital System - <span class="product-label-link" type="condition" conceptid="4090870" conceptname="Spasm of bladder">Bladder spasms</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span>, <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">Incontinence</span>, <span class="product-label-link" type="condition" conceptid="4270932" conceptname="Pain in testicle">Testicular pain</span>, Urinary obstruction; Miscellaneous - <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>/<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>, Increased BUN, Increased calcium, Increased creatinine, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>/<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, Ophthalmologic disorders, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> (temporal bone).<br> </p>
<p>In an additional clinical trial and from long-term observation of both studies, the following additional adverse events (excluding those considered not drug related) were reported for patients receiving leuprolide acetate injection.</p>
<br><p>Cardiovascular System - <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4304563" conceptname="Carotid bruit">Carotid bruit</span>, Extrasystole, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span>, Perivascular cuffing (eyes), Ruptured <span class="product-label-link" type="condition" conceptid="317585" conceptname="Aortic aneurysm">aortic aneurysm</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, Transient ischemic attack; Gastrointestinal System - <span class="product-label-link" type="condition" conceptid="4091513" conceptname="Passing flatus">Flatus</span>, Dryness of mouth and throat, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span>, Occult blood (rectal exam), <span class="product-label-link" type="condition" conceptid="193807" conceptname="Anorectal fistula">Rectal fistula</span>/<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>; Endocrine System - Libido increase, <span class="product-label-link" type="condition" conceptid="4030041" conceptname="Thyroid nodule">Thyroid nodule</span>; Musculoskeletal System - Ankylosing <span class="product-label-link" type="condition" conceptid="74130" conceptname="Thoracic spondylosis without myelopathy">spondylosis</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span>, Blurred disc margins, Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">Muscle stiffness</span>, Muscle <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="4318540" conceptname="Fibrosis of pelvic cavity">Pelvic fibrosis</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Spasms</span>/<span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>; Central/Peripheral Nervous System - <span class="product-label-link" type="condition" conceptid="4164151" conceptname="Auditory hallucinations">Auditory hallucinations</span>/<span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, Decreased hearing, Decreased reflexes, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">Euphoria</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">Hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="4185711" conceptname="Loss of sense of smell">Loss of smell</span>, Motor deficiency; Respiratory System - <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">Chest tightness</span>, Decreased breathing sounds, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">Hemoptysis</span>, Pleuritic <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, Pulmonary infiltrate, <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">Rales</span>/<span class="product-label-link" type="condition" conceptid="4084392" conceptname="Wheeze - rhonchi">rhonchi</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span>, Strep throat, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">Wheezing</span>/<span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>; Integumentary System - <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">Boil</span> (pubic), <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Bruises</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Hives</span>, <span class="product-label-link" type="condition" conceptid="4098436" conceptname="Hyperkeratosis">Keratosis</span>, Mole, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Shingles</span>, Spiders; Urogenital System - <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blisters</span> on penis, <span class="product-label-link" type="condition" conceptid="4288544" conceptname="Inguinal hernia">Inguinal hernia</span>, <span class="product-label-link" type="condition" conceptid="4224222" conceptname="Penile swelling">Penile swelling</span>, Post void residual, <span class="product-label-link" type="condition" conceptid="4280580" conceptname="Prostatic pain">Prostatic pain</span>, <span class="product-label-link" type="condition" conceptid="4167328" conceptname="Pyuria">Pyuria</span>; Miscellaneous - Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">Facial swelling</span>/<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, Feet burning, Flu, Eyelid growth, <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">Hypoproteinemia</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental injury</span>, <span class="product-label-link" type="condition" conceptid="72407" conceptname="Effusion of joint of shoulder region">Knee effusion</span>, <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span>, Pallid, Sallow, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>.<br> </p>
<span><a name="s8.2"></a></span><span><a name="section-9.2"></a></span><p>Postmarketing </p>
<p>During postmarketing surveillance which includes other dosage forms and other patient populations, the following adverse events were reported.</p>
<br><p>Symptoms consistent with an anaphylactoid or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> process have been rarely (incidence rate of about 0.002%) reported. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reactions</span> have also been reported. </p>
<br><p>Localized reactions including <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> and <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> have been reported at the site of injection.</p>
<br><p>Symptoms consistent with <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> (e.g., joint and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorders</span>, gastrointestinal distress, and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>) have been reported individually and collectively.</p>
<br><p>Cardiovascular System – <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>; Endocrine System - <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span>; Gastrointestinal System – Hepatic dysfunction; Hemic and Lymphatic System – Decreased WBC; Integumentary System – Hair growth; Central/Peripheral Nervous System – <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsion</span>, <span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Spinal fracture</span>/<span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, Hearing disorder; Miscellaneous – Hard <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodule</span> in throat, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span>, Increased uric acid; Musculoskeletal System – <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">Tenosynovitis</span>-like symptoms; Respiratory System – <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory disorders</span>.</p>
<br><p><span><a name="s8.2.1"></a></span><span><a name="section-9.2.1"></a></span>Changes in Bone Density: Decreased bone density has been reported in the medical literature in men who have had orchiectomy or who have been treated with an LH-RH agonist analog. In a clinical trial, 25 men with prostate cancer, 12 of whom had been treated previously with leuprolide acetate for at least six months, underwent bone density studies as a result of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. The leuprolide-treated group had lower bone density scores than the nontreated control group. It can be anticipated that long periods of medical castration in men will have effects on bone density. </p>
<br><p><span><a name="s8.2.2"></a></span><span><a name="section-9.2.2"></a></span><span class="product-label-link" type="condition" conceptid="4129534" conceptname="Pituitary apoplexy">Pituitary apoplexy</span>: During postmarketing surveillance, rare cases of <span class="product-label-link" type="condition" conceptid="4129534" conceptname="Pituitary apoplexy">pituitary apoplexy</span> (a clinical syndrome secondary to <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> of the pituitary gland) have been reported after the administration of gonadotropin-releasing hormone agonists. In a majority of these cases, a <span class="product-label-link" type="condition" conceptid="437251" conceptname="Benign neoplasm of pituitary gland and craniopharyngeal duct">pituitary adenoma</span> was diagnosed, with a majority of <span class="product-label-link" type="condition" conceptid="4129534" conceptname="Pituitary apoplexy">pituitary apoplexy</span> cases occurring within 2 weeks of the first dose, and some within the first hour. In these cases, <span class="product-label-link" type="condition" conceptid="4129534" conceptname="Pituitary apoplexy">pituitary apoplexy</span> has presented as sudden <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, visual changes, <span class="product-label-link" type="condition" conceptid="4052337" conceptname="Ophthalmoplegia">ophthalmoplegia</span>, altered mental status, and sometimes <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>. Immediate medical attention has been required.</p>
<br><p>See other LUPRON DEPOT* and leuprolide acetate injection package inserts for other events reported in the same and different patient populations.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_9"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In rats subcutaneous administration of 250 to 500 times the recommended human dose, expressed on a per body weight basis, resulted in <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">decreased activity</span>, and local irritation at the injection site. There is no evidence at present that there is a clinical counterpart of this phenomenon. In early clinical trials with leuprolide acetate doses as high as 20 mg/day for up to two years caused no adverse effects differing from those observed with the 1 mg/day dose.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_10"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose is 1 mg (0.2 mL or 20 unit mark) administered as a single daily subcutaneous injection. As with other drugs administered chronically by subcutaneous injection, the injection site should be varied periodically. Each 0.2 mL contains 1 mg of leuprolide acetate, sodium chloride for tonicity adjustment, 1.8 mg of benzyl alcohol as preservative and water for injection. The pH may have been adjusted with sodium hydroxide and/or glacial acetic acid.</p>
<br><p>Follow the pictorial directions on the reverse side of this package insert for administration.</p>
<br><p>NOTE: As with all parenteral products, inspect the solution for discoloration and particulate matter before each use.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_11"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Leuprolide acetate injection is a sterile solution supplied in a 2.8 mL multiple-dose vial. The vial is packaged as follows: 14 Day Patient Administration Kit with 14 disposable syringes and 28 alcohol swabs, NDC 47335-936-40 </p>
<br><p>Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Do not freeze. Protect from light; store vial in carton until use.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="Section_14"></a><a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<ol class="Arabic">
<li>NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.</li>
<li>OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. <span class="Underline">http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html </span>
</li>
<li>American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. <span class="Italics">Am J Health-Syst Pharm</span>. 2006; 63; 1172-1193. </li>
<li>Polovich, M., White, J.M., &amp; Kelleher, L.O. (eds.) 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2nd Ed.) Pittsburgh, PA: Oncology Nursing Society.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="Section_15"></a><a name="section-13"></a><p></p>
<h1>INFORMATION FOR PATIENTS</h1>
<p class="First">Be sure to consult your physician with any questions you may have or for information about leuprolide acetate injection and its use.</p>
<br><p><span class="Bold">WHAT IS LEUPROLIDE ACETATE INJECTION?</span><span class="Bold"></span></p>
<p>Leuprolide acetate injection is chemically similar to gonadotropin releasing hormone (GnRH or LH-RH) a hormone which occurs naturally in your body.</p>
<br><p>Normally, your body releases small amounts of LH-RH and this leads to events which stimulate the production of sex hormones.</p>
<br><p>However, when you inject leuprolide acetate injection, the normal events that lead to sex hormone production are interrupted and testosterone is no longer produced by the testes.</p>
<br><p>Leuprolide acetate injection must be injected because, like insulin which is injected by diabetics, leuprolide acetate injection is inactive when taken by mouth.</p>
<br><p>If you were to discontinue the drug for any reason, your body would begin making testosterone again.</p>
<br><p><span class="Bold">DIRECTIONS FOR USING LEUPROLIDE ACETATE INJECTION</span><span class="Bold"></span></p>
<ol class="Arabic">
<li>Wash hands thoroughly with soap and water. </li>
<li>If using a new bottle for the first time, flip off the plastic cover to expose the grey rubber stopper. Wipe metal ring and rubber stopper with an alcohol wipe each time you use leuprolide acetate injection. Check the liquid in the container. If it is not clear or has particles in it, DO NOT USE IT. Exchange it at your pharmacy for another container. </li>
<li>Remove outer wrapping from one syringe. Pull plunger back until the tip of the plunger is at the 0.2 mL or 20 unit mark. </li>
<li>Take cover off needle. Push the needle through the center of the rubber stopper on the leuprolide acetate injection bottle. </li>
<li>Push the plunger all the way in to inject air into the bottle. </li>
<li>Keep the needle in the bottle and turn the bottle upside down. Check to make sure the tip of the needle is in the liquid. Slowly pull back on the plunger, until the syringe fills to the 0.2 mL or 20 unit mark. </li>
<li>Toward the end of a two-week period, the amount of leuprolide acetate injection left in the bottle will be small. Take special care to hold the bottle straight and to keep the needle tip in liquid while pulling back on the plunger. </li>
<li>Keeping the needle in the bottle and the bottle upside down, check for air bubbles in the syringe. If you see any, push the plunger slowly in to push the air bubble back into the bottle. Keep the tip of the needle in the liquid and pull the plunger back again to fill to the 0.2 mL or 20 unit mark. </li>
<li>Do this again if necessary to eliminate air bubbles. </li>
<li> To protect your skin, inject each daily dose at a different body spot. </li>
<li>Choose an injection spot. Cleanse the injection spot with another alcohol wipe. </li>
<li>Hold the syringe in one hand. Hold the skin taut, or pull up a little flesh with the other hand, as you were instructed. </li>
<li>Holding the syringe as you would a pencil, thrust the needle all the way into the skin at a 90° angle. Push the plunger to administer the injection. </li>
<li>Hold an alcohol wipe down on your skin where the needle is inserted and withdraw the needle at the same angle it was inserted. </li>
<li>Use the disposable syringe only once and dispose of it properly as you were instructed. Needles thrown into a garbage bag could accidentally stick someone. NEVER LEAVE SYRINGES, NEEDLES OR DRUGS WHERE CHILDREN CAN REACH THEM. </li>
</ol>
<br><p><span class="Bold">SOME SPECIAL ADVICE</span><span class="Bold"></span></p>
<ul class="Disc">
<li>You may experience <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span> when using leuprolide acetate injection. During the first few weeks of treatment you may experience increased <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, increased difficulty in urinating, and less commonly but most importantly, you may experience the onset or aggravation of nerve symptoms. In any of these events, discuss the symptoms with your doctor. Like other treatment options, leuprolide acetate injection may cause <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>. Notify your doctor if you develop new or worsened symptoms after beginning leuprolide acetate injection treatment. </li>
<li>You may experience some irritation at the injection site, such as burning, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>. These reactions are usually mild and go away. If they do not, tell your doctor. </li>
<li>If you have experienced an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to other drugs like leuprolide acetate injection, you should not use this drug. </li>
<li>Do not stop taking your injections because you feel better. You need an injection every day to make sure leuprolide acetate injection keeps working for you. </li>
<li>If you need to use an alternate to the syringe supplied with leuprolide acetate injection, low-dose insulin syringes should be utilized. </li>
<li>When the drug level gets low, take special care to hold the bottle straight up and down and to keep the needle tip in liquid while pulling back on the plunger. </li>
<li>Do not try to get every last drop out of the bottle. This will increase the possibility of drawing air into the syringe and getting an incomplete dose. Some extra drug has been provided so that you can withdraw the recommended number of doses. </li>
<li>Tell your pharmacist when you will need leuprolide acetate injection so it will be at the pharmacy when you need it. </li>
<li>Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). Do not store near a radiator or other very warm place. Do not freeze. Protect from light; store vial in carton until use. </li>
<li>Do not leave your drug or hypodermic syringes where anyone can pick them up. </li>
<li>Keep this and all other medications out of reach of children. </li>
</ul>
<br><p>*The following is a registered trademark of its respective manufacturer: LUPRON DEPOT<span class="Sup">®</span>/TAP Pharmaceuticals Inc.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_1"></a><a name="section-14"></a><p></p>
<h1>FOR PEDIATRIC USE</h1>
<p class="First">Leuprolide Acetate Injection<br><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_2"></a><a name="section-15"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin releasing hormone (GnRH or LH-RH). The analog possesses greater potency than the natural hormone. The chemical name is 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide acetate (salt) with the following structural formula:</p>
<br><div class="Figure"><img alt="leuprolide-structure-pediatric" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3b01473-30c7-4945-bd60-2484221aaaad&amp;name=leuprolide-structure-pediatric.jpg"></div>
<br><p>Leuprolide acetate injection is a sterile, aqueous solution intended for daily subcutaneous injection.</p>
<br><p>It is available in a 2.8 mL multiple dose vial containing leuprolide acetate [leuprorelin Ph Eur] (5 mg/mL), sodium chloride, USP (6.3 mg/mL) for tonicity adjustment, benzyl alcohol, NF as a preservative (9 mg/mL), and water for injection, USP. The pH may have been adjusted with sodium hydroxide, NF and/or glacial acetic acid, USP.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_3"></a><a name="section-16"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Leuprolide acetate, a GnRH agonist, acts as a potent inhibitor of gonadotropin secretion when given continuously and in therapeutic doses. Animal and human studies indicate that following an initial stimulation of gonadotropins, chronic administration of leuprolide acetate results in suppression of ovarian and testicular steroidogenesis. This effect is reversible upon discontinuation of drug therapy.</p>
<br><p>Leuprolide acetate is not active when given orally.</p>
<br><span><a name="s14.2.1"></a></span><span><a name="section-17.1"></a></span><p>Pharmacokinetics</p>
<p>A pharmacokinetic study of leuprolide acetate in children has not been performed.</p>
<br><span><a name="s14.2.1.1"></a></span><span><a name="section-17.1.1"></a></span><p>Absorption </p>
<p>In adults, bioavailability by subcutaneous administration is comparable to that by intravenous administration.</p>
<br><span><a name="s14.2.1.2"></a></span><span><a name="section-17.1.2"></a></span><p>Distribution </p>
<p>The mean steady-state volume of distribution of leuprolide following intravenous bolus administration to healthy adult male volunteers was 27 L. <span class="Italics">In vitro</span> binding to human plasma proteins ranged from 43% to 49%.</p>
<br><span><a name="s14.2.1.3"></a></span><span><a name="section-17.1.3"></a></span><p>Metabolism </p>
<p>In healthy adult male volunteers, a 1 mg bolus of leuprolide administered intravenously revealed that the mean systemic clearance was 7.6 L/h, with a terminal elimination half-life of approximately 3 hours based on a two compartment model.</p>
<br><p>In rats and dogs, administration of <span class="Sup">14</span>C-labeled leuprolide was shown to be metabolized to smaller inactive peptides, a pentapeptide (Metabolite I), tripeptides (Metabolites II and III) and a dipeptide (Metabolite IV). These fragments may be further catabolized.</p>
<br><p>The major metabolite (M-I) plasma concentrations measured in 5 prostate cancer patients reached maximum concentration 2 to 6 hours after dosing and were approximately 6% of the peak parent drug concentration. One week after dosing, mean plasma M-I concentrations were approximately 20% of mean leuprolide concentrations.</p>
<br><span><a name="s14.2.1.4"></a></span><span><a name="section-17.1.4"></a></span><p>Excretion </p>
<p>Following administration of LUPRON DEPOT* 3.75 mg to three adult patients, less than 5% of the dose was recovered as parent and M-I metabolite in the urine.</p>
<br><span><a name="s14.2.2"></a></span><span><a name="section-17.1.5"></a></span><p>Special Populations </p>
<p>The pharmacokinetics of the drug in hepatically and renally impaired patients has not been determined.</p>
<p>Drug Interactions<br>No pharmacokinetic-based drug-drug interaction studies have been conducted with leuprolide acetate. However, because leuprolide acetate is a peptide that is primarily degraded by peptidase and the drug is only about 46% bound to plasma proteins, drug interactions would not be expected to occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_4"></a><a name="section-17"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">In children with central <span class="product-label-link" type="condition" conceptid="4267558" conceptname="Precocious puberty">precocious puberty</span> (CPP), stimulated and basal gonadotropins are reduced to prepubertal levels. Testosterone and estradiol are reduced to prepubertal levels in males and females respectively. Reduction of gonadotropins will allow for normal physical and psychological growth and development. Natural maturation occurs when gonadotropins return to pubertal levels following discontinuation of leuprolide acetate.</p>
<br><p>The following physiologic effects have been noted with the chronic administration of leuprolide acetate in this patient population.</p>
<br><ol class="Arabic">
<li>
<span class="Bold">Skeletal Growth.</span> A measurable increase in body length can be noted since the epiphyseal plates will not close prematurely. </li>
<li>
<span class="Bold">Organ Growth.</span> Reproductive organs will return to a prepubertal state. </li>
<li>
<span class="Bold">Menses.</span> Menses, if present, will cease.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_5"></a><a name="section-18"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Leuprolide acetate injection is indicated in the treatment of children with central <span class="product-label-link" type="condition" conceptid="4267558" conceptname="Precocious puberty">precocious puberty</span>. Children should be selected using the following criteria:</p>
<br><p>        1. Clinical diagnosis of CPP (idiopathic or neurogenic) with onset of secondary sexual characteristics earlier than 8 years in females and 9 years in males. <br>        2. Clinical diagnosis should be confirmed prior to initiation of therapy:</p>
<ul class="Disc">
<li>Confirmation of diagnosis by a pubertal response to a GnRH stimulation test. The sensitivity and methodology of this assay must be understood.</li>
<li>Bone age advanced 1 year beyond the chronological age.</li>
</ul>
<p>         3. Baseline evaluation should also include: </p>
<ul class="Disc">
<li>Height and weight measurements. </li>
<li>Sex steroid levels. </li>
<li>Adrenal steroid level to exclude congenital adrenal <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>. </li>
<li>Beta human chorionic gonadotropin level to rule out a chorionic gonadotropin secreting tumor. </li>
<li>Pelvic/adrenal/testicular ultrasound to rule out a steroid secreting tumor. </li>
<li>Computerized tomography of the head to rule out intracranial tumor.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_6"></a><a name="section-19"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<ol class="Arabic">
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to GnRH, GnRH agonist analogs or any of the excipients in leuprolide acetate injection. Reports of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to GnRH agonist analogs have been reported in the medical literature. </li>
<li>Leuprolide acetate injection is contraindicated in women who are or may become pregnant while receiving the drug. Leuprolide acetate injection may cause fetal harm when administered to a pregnant woman. Major fetal abnormalities were observed in rabbits but not in rats after administration of leuprolide acetate throughout gestation. There was increased fetal mortality and decreased fetal weights in rats and rabbits. (See <a href="#Unclassified_Section_8">PRECAUTIONS</a>,  Pregnancy, Teratogenic Effects section.) The effects on fetal mortality are expected consequences of the alterations in hormonal levels brought about by this drug. Therefore, the possibility exists that <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span> may occur if the drug is administered during pregnancy. If this drug is administered during pregnancy or if the patient becomes pregnant while taking leuprolide acetate injection, the patient should be apprised of the potential hazard to the fetus. </li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_7"></a><a name="section-20"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">During the early phase of therapy, gonadotropins and sex steroids rise above baseline because of the natural stimulatory effect of the drug. Therefore, an increase in clinical signs and symptoms may be observed (see <a href="#Unclassified_Section_3">CLINICAL PHARMACOLOGY</a> section).</p>
<br><p>Noncompliance with drug regimen or inadequate dosing may result in inadequate control of the pubertal process. The consequences of poor control include the return of pubertal signs such as menses, breast development, and testicular growth. The long-term consequences of inadequate control of gonadal steroid secretion are unknown, but may include a further compromise of adult stature.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_8"></a><a name="section-21"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Patients with known allergies to benzyl alcohol, an ingredient of the vehicle of leuprolide acetate injection, may present symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, usually local, in the form of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> and <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> at the injection site.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_8.2"></a><a name="section-21.1"></a><p></p>
<h2>Information for Parents</h2>
<p class="First">Prior to starting therapy with leuprolide acetate injection, the parent or guardian must be aware of the importance of continuous therapy. Adherence to daily drug administration schedules must be accepted if therapy is to be successful. Irregular dosing could restart the maturation process.</p>
<br><ul class="Disc">
<li>During the first 2 months of therapy, a female may experience menses or spotting. If <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> continues beyond the second month, notify the physician. </li>
<li>Any irritation at the injection site should be reported to the physician immediately. If the child has experienced an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to other drugs like leuprolide acetate injection, this drug should not be used. </li>
<li>Report any unusual signs or symptoms to the physician, like continued pubertal changes, substantial <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span> or behavioral changes.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_8.1"></a><a name="section-21.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Response to leuprolide acetate should be monitored 1 to 2 months after the start of therapy with a GnRH stimulation test and sex steroid levels. Measurement of bone age for advancement should be done every 6 to 12 months.</p>
<br><p>Sex steroids may increase or rise above prepubertal levels if the dose is inadequate (see <a href="#Unclassified_Section_7">WARNINGS</a> section). Once a therapeutic dose has been established, gonadotropin and sex steroid levels will decline to prepubertal levels.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_8.3"></a><a name="section-21.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">See <a href="#Unclassified_Section_3">CLINICAL PHARMACOLOGY</a>,  Pharmacokinetics section.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_8.4"></a><a name="section-21.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Administration of leuprolide acetate in therapeutic doses results in suppression of the pituitary-gonadal system. Normal function is usually restored within 4 to 12 weeks after treatment is discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_8.5"></a><a name="section-21.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">A two-year carcinogenicity study was conducted in rats and mice. In rats, a dose-related increase of benign pituitary <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and benign <span class="product-label-link" type="condition" conceptid="437251" conceptname="Benign neoplasm of pituitary gland and craniopharyngeal duct">pituitary adenomas</span> was noted at 24 months when the drug was administered subcutaneously at high daily doses of 0.6 to 4 mg/kg (&gt;100 times the clinical doses of 7.5 to 15 mg/month based on body surface area). There was a significant but not dose-related increase of pancreatic islet-cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in females and of testes interstitial cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in males (highest incidence in the low dose group). In mice, no leuprolide acetate-induced tumors or pituitary abnormalities were observed at daily dose as high as 60 mg/kg (&gt;5000 times the clinical doses based on body surface area). Adult patients have been treated with leuprolide acetate for up to three years with doses as high as 10 mg/day and for two years with doses as high as 20 mg/day without demonstrable pituitary abnormalities.</p>
<br><p>Although no clinical studies have been completed in children to assess the full reversibility of fertility suppression, animal studies (prepubertal and adult rats and monkeys) with leuprolide acetate and other GnRH analogs have shown functional recovery. However, following a study with leuprolide acetate, immature male rats demonstrated tubular degeneration in the testes even after a recovery period. In spite of the failure to recover histologically, the treated males proved to be as fertile as the controls. Also, no histologic changes were observed in the female rats following the same protocol. In both sexes, the offspring of the treated animals appeared normal. The effect of the treatment of the parents on the reproductive performance of the F1 generation was not tested. The clinical significance of these findings is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_8.6"></a><a name="section-21.6"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">Teratogenic Effects</p>
<span><a name="s14.7.6.1.1"></a></span><span><a name="section-22.6.1.1"></a></span><p><span class="Italics">Pregnancy Category X</span></p>
<p>(see <a href="#Unclassified_Section_6">CONTRAINDICATIONS</a> section)</p>
<p>When administered on day 6 of pregnancy at test dosages of 0.00024, 0.0024, and 0.024 mg/kg (1/1200 to 1/12 the human pediatric dose) to rabbits, leuprolide acetate injection produced a dose-related increase in major fetal abnormalities. Similar studies in rats failed to demonstrate an increase in <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>. There was increased fetal mortality and decreased fetal weights with the two higher doses of leuprolide acetate injection in rabbits and with the highest dose in rats.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_8.7"></a><a name="section-21.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether leuprolide acetate is excreted in human milk. Leuprolide acetate injection should not be used by nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_8.8"></a><a name="section-21.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">See labeling for leuprolide acetate injection for the pharmacokinetics, efficacy and safety of leuprolide acetate injection in this population.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_9"></a><a name="section-22"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Clinical Trials</p>
<p>Potential exacerbation of signs and symptoms during the first few weeks of treatment (see <a href="#Unclassified_Section_8">PRECAUTIONS</a> section) is a concern in patients with rapidly advancing central <span class="product-label-link" type="condition" conceptid="4267558" conceptname="Precocious puberty">precocious puberty</span>.</p>
<br><p>In two studies of children with central <span class="product-label-link" type="condition" conceptid="4267558" conceptname="Precocious puberty">precocious puberty</span>, in 2% or more of the patients receiving the drug, the following adverse reactions were reported to have a possible or probable relationship to drug as ascribed by the treating physician. Reactions considered not drug related are excluded.<span><a name="t2"></a></span></p>
<br><br><table border="0" cellpadding="0" cellspacing="0" width="499">
<tfoot><tr><td colspan="0" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Most events were mild or moderate in severity.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" rowspan="2" valign="top"> <br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold">Number of Patients</span><span class="Bold"></span><br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="2" valign="top">
<span class="Bold">N = 421 (Percent)</span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Body as a Whole <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">General <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> <br>
</td>
<td class="Rrule" align="center" valign="top">12<br>
</td>
<td class="Rrule" align="center" valign="top">(3)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> <br>
</td>
<td class="Rrule" align="center" valign="top">11<br>
</td>
<td class="Rrule" align="center" valign="top">(3)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection Site Reactions</span> Including <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscess</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a><br>
</td>
<td class="Rrule" align="center" valign="top">37<br>
</td>
<td class="Rrule" align="center" valign="top">(9)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Cardiovascular System <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Vasodilation <br>
</td>
<td class="Rrule" align="center" valign="top">9<br>
</td>
<td class="Rrule" align="center" valign="top">(2)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Integumentary System (Skin and Appendages) <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>/<span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">Seborrhea</span> <br>
</td>
<td class="Rrule" align="center" valign="top">13<br>
</td>
<td class="Rrule" align="center" valign="top">(3)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> Including <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema Multiforme</span> <br>
</td>
<td class="Rrule" align="center" valign="top">12<br>
</td>
<td class="Rrule" align="center" valign="top">(3)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Nervous System <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Emotional Lability</span> <br>
</td>
<td class="Rrule" align="center" valign="top">19<br>
</td>
<td class="Rrule" align="center" valign="top">(5)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Urogenital System <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span>/<span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span>/<span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">Vaginal Discharge</span> <br>
</td>
<td class="Rrule" align="center" valign="top">13<br>
</td>
<td class="Rrule" align="center" valign="top">(3)<br>
</td>
</tr>
</tbody>
</table>
<p>  </p>
<p>In those same studies, the following adverse reactions were reported in less than 2% of the patients.</p>
<p><span class="Italics">Body as a Whole</span> – Aggravation of preexisting tumor and decreased vision, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reaction</span>, <span class="product-label-link" type="condition" conceptid="4178504" conceptname="Body odor">Body Odor</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu Syndrome</span>, <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">Hypertrophy</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>; <span class="Italics">Cardiovascular System</span> – <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>, <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral Vascular Disorder</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>; <span class="Italics">Digestive System</span> – <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">Gingivitis</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased Appetite</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>; <span class="Italics">Endocrine System</span> -<span class="product-label-link" type="condition" conceptid="4267558" conceptname="Precocious puberty">Accelerated Sexual Maturity</span>, <span class="product-label-link" type="condition" conceptid="4140373" conceptname="Feminized male">Feminization</span>, <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">Goiter</span>; <span class="Italics">Hemic and Lymphatic System</span> – <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">Purpura</span>; <span class="Italics">Metabolic and Nutritional Disorders</span> – <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">Growth Retarded</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span>; <span class="Italics">Musculoskeletal System</span> – <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">Joint Disorder</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>; <span class="Italics">Nervous System</span> – <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">Hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>; <span class="Italics">Respiratory System</span> – <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span>; <span class="Italics">Integumentary System (Skin and Appendages)</span> - <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="4199168" conceptname="Wooly hair">Hair Disorder</span>, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span>, <span class="product-label-link" type="condition" conceptid="4041510" conceptname="Skin hypopigmented">Leukoderma</span>, <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">Nail Disorder</span>, Skin <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">Hypertrophy</span>;<span class="Italics"> Urogenital System</span> - <span class="product-label-link" type="condition" conceptid="194088" conceptname="Hypertrophic elongation of cervix">Cervix Disorder</span>/Neoplasm, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Dysmenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span>/<span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span>, <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">Menstrual Disorder</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary Incontinence</span>. </p>
<br><p><span class="Italics">Laboratory:</span> The following laboratory events were reported as adverse reactions, <span class="product-label-link" type="condition" conceptid="4149302" conceptname="Sm antibody positive">antinuclear antibody present</span> and increased sedimentation rate.</p>
<span><a name="s14.8.2"></a></span><span><a name="section-23.2"></a></span><p>Postmarketing </p>
<p>During postmarketing surveillance, which includes other dosage forms and other patient populations, the following adverse events were reported.</p>
<br><p>Symptoms consistent with an anaphylactoid or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> process have been rarely (incidence rate of about 0.002%) reported. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reactions</span> have also been reported. Localized reactions including <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> and <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> have been reported at the site of injection. Symptoms consistent with <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> (e.g., joint and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorders</span>, gastrointestinal distress, and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>) have been reported individually and collectively.</p>
<br><p>Cardiovascular System – <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span>; Gastrointestinal System – Hepatic dysfunction; Hemic and Lymphatic System – Decreased WBC; Integumentary System – Hair growth; Central/Peripheral Nervous System – <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsion</span>, <span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Spinal fracture</span>/<span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, Hearing disorder; Miscellaneous – Hard <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodule</span> in throat, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span>, Increased uric acid; Musculoskeletal System – <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">Tenosynovitis</span>-like symptoms; Respiratory System – <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory disorders</span>; Urogenital System – Prostate <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<br><p><span><a name="s14.8.2.1"></a></span><span><a name="section-23.2.1"></a></span>Changes in Bone Density: Decreased bone density has been reported in the medical literature in men who have had orchiectomy or who have been treated with an LH-RH agonist analog. In a clinical trial, 25 men with prostate cancer, 12 of whom had been treated previously with leuprolide acetate for at least six months, underwent bone density studies as a result of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. The leuprolide-treated group had lower bone density scores than the nontreated control group. The effects on bone density in children are unknown.</p>
<p><span class="product-label-link" type="condition" conceptid="4129534" conceptname="Pituitary apoplexy">Pituitary apoplexy</span>: During postmarketing surveillance, rare cases of <span class="product-label-link" type="condition" conceptid="4129534" conceptname="Pituitary apoplexy">pituitary apoplexy</span> (a clinical syndrome secondary to <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> of the pituitary gland) have been reported after the administration of gonadotropin-releasing hormone agonists. In a majority of these cases, a <span class="product-label-link" type="condition" conceptid="437251" conceptname="Benign neoplasm of pituitary gland and craniopharyngeal duct">pituitary adenoma</span> was diagnosed, with a majority of <span class="product-label-link" type="condition" conceptid="4129534" conceptname="Pituitary apoplexy">pituitary apoplexy</span> cases occurring within 2 weeks of the first dose, and some within the first hour. In these cases, <span class="product-label-link" type="condition" conceptid="4129534" conceptname="Pituitary apoplexy">pituitary apoplexy</span> has presented as sudden <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, visual changes, <span class="product-label-link" type="condition" conceptid="4052337" conceptname="Ophthalmoplegia">ophthalmoplegia</span>, altered mental status, and sometimes <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>. Immediate medical attention has been required.</p>
<br><p>See other leuprolide acetate injection and LUPRON DEPOT* package inserts for adverse events reported in other patient populations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_10"></a><a name="section-23"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In rats, subcutaneous administration of 125 to 250 times the recommended human pediatric dose, expressed on a per body weight basis, resulted in <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">decreased activity</span>, and local irritation at the injection site. There is no evidence at present that there is a clinical counterpart of this phenomenon. In early clinical trials using leuprolide acetate in adult patients, doses as high as 20 mg/day for up to two years caused no adverse effects differing from those observed with the 1 mg/day dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_11"></a><a name="section-24"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Leuprolide acetate injection can be administered by a patient/parent or health care professional.</p>
<br><p>The dose of leuprolide acetate injection must be individualized for each child. The dose is based on a mg/kg ratio of drug to body weight. Younger children require higher doses on a mg/kg ratio.</p>
<br><p>After 1 to 2 months of initiating therapy or changing doses, the child must be monitored with a GnRH stimulation test, sex steroids, and Tanner staging to confirm downregulation. Measurements of bone age for advancement should be monitored every 6 to 12 months. The dose should be titrated upward until no progression of the condition is noted either clinically and/or by laboratory parameters.</p>
<br><p>The first dose found to result in adequate downregulation can probably be maintained for the duration of therapy in most children. However, there are insufficient data to guide dosage adjustment as patients move into higher weight categories after beginning therapy at very young ages and low dosages. It is recommended that adequate downregulation be verified in such patients whose weight has increased significantly while on therapy.</p>
<br><p>As with other drugs administered by injection, the injection site should be varied periodically.</p>
<br><p>Discontinuation of leuprolide acetate injection should be considered before age 11 for females and age 12 for males.</p>
<br><p>The recommended starting dose is 50 mcg/kg/day administered as a single subcutaneous injection. If total downregulation is not achieved, the dose should be titrated upward by 10 mcg/kg/day. This dose will be considered the maintenance dose.</p>
<br><p>Follow the pictorial directions at the end of this package insert for administration.</p>
<br><p>NOTE: As with other parenteral products, inspect the solution for discoloration and particulate matter before each use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_12"></a><a name="section-25"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Leuprolide acetate injection is a sterile solution supplied in a 2.8 mL multiple-dose vial. The vial is packaged as follows:</p>
<br><ul class="Disc"><li>14 Day Patient Administration Kit with 14 disposable syringes (Use the syringes supplied with leuprolide acetate injection) and 28 alcohol swabs, NDC 47335-936-40. </li></ul>
<br><p>Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Do not freeze. Protect from light; store vial in carton until use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_13"></a><a name="section-26"></a><p></p>
<h1>REFERENCES</h1>
<ol class="Arabic">
<li>NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165. </li>
<li>OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. <span class="Underline">http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html </span>
</li>
<li>American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. <span class="Italics">Am J Health-Syst Pharm</span>. 2006; 63; 1172-1193. </li>
<li>Polovich, M., White, J.M., &amp; Kelleher, L.O. (eds.) 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2nd Ed.) Pittsburgh, PA: Oncology Nursing Society.</li>
</ol>
<br><p class="First">*The following is a registered trademark of its respective manufacturer: LUPRON DEPOT<span class="Sup">®</span>/TAP Pharmaceuticals Inc.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_14"></a><a name="section-27"></a><p></p>
<h1>Administering the Injection</h1>
<p class="First"><span class="Bold">Patient medication guide included.<br><img alt="leuprolide-fig-1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3b01473-30c7-4945-bd60-2484221aaaad&amp;name=leuprolide-fig-1.jpg"><br><img alt="leuprolide-fig-2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3b01473-30c7-4945-bd60-2484221aaaad&amp;name=leuprolide-fig-2.jpg"><br><img alt="leuprolide-fig-3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3b01473-30c7-4945-bd60-2484221aaaad&amp;name=leuprolide-fig-3.jpg"><br><img alt="leuprolide-fig-4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3b01473-30c7-4945-bd60-2484221aaaad&amp;name=leuprolide-fig-4.jpg"><br><img alt="leuprolide-fig-5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3b01473-30c7-4945-bd60-2484221aaaad&amp;name=leuprolide-fig-5.jpg"><br><img alt="leuprolide-fig-6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3b01473-30c7-4945-bd60-2484221aaaad&amp;name=leuprolide-fig-6.jpg"><br><img alt="leuprolide-fig-7" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3b01473-30c7-4945-bd60-2484221aaaad&amp;name=leuprolide-fig-7.jpg"><br><img alt="leuprolide-fig-8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3b01473-30c7-4945-bd60-2484221aaaad&amp;name=leuprolide-fig-8.jpg"><br><img alt="leuprolide-fig-9" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3b01473-30c7-4945-bd60-2484221aaaad&amp;name=leuprolide-fig-9.jpg"><br><img alt="leuprolide-fig-10" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3b01473-30c7-4945-bd60-2484221aaaad&amp;name=leuprolide-fig-10.jpg"><br><img alt="leuprolide-fig-11" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3b01473-30c7-4945-bd60-2484221aaaad&amp;name=leuprolide-fig-11.jpg"><br><img alt="leuprolide-fig-12" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3b01473-30c7-4945-bd60-2484221aaaad&amp;name=leuprolide-fig-12.jpg"><br></span>Distributed by: <br><span class="Bold">Sun Pharmaceutical Industries, Inc. <br></span>Cranbury, NJ 08512<br><br>ISS.11/2014 <br>PJPI0513</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_17"></a><a name="section-28"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL_Vial Label</h1>
<br><p class="First"><span class="Bold">NDC 47335-936-40<br>2.8 mL Multiple-dose <br>Sterile Injection Vial<br>Leuprolide Acetate Injection<br>14 mg/2.8 mL(1 mg/0.2 mL)<br>For subcutaneous injection<br>Rx only<br><img alt="leuprolide_label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3b01473-30c7-4945-bd60-2484221aaaad&amp;name=leuprolide_label.jpg"></span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_18"></a><a name="section-29"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL_Inner Carton</h1>
<p class="First"><span class="Bold">NDC 47335-936-40 <br>2.8 mL Multiple-dose <br>Sterile Injection Vial<br>Leuprolide Acetate Injection <br>14 mg/2.8 mL(1 mg/0.2 mL)<br>For subcutaneous injection<br>Rx only<br>SUN PHARMA<br><img alt="leuprolide_innercarton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3b01473-30c7-4945-bd60-2484221aaaad&amp;name=leuprolide_innercarton.jpg"><br></span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_19"></a><a name="section-30"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL_Outer Carton</h1>
<p class="First"><span class="Bold">NDC 47335-936-40 <br>Leuprolide Acetate Injection<br>14 mg/2.8 mL(1 mg/0.2 mL)<br>For subcutaneous injection <br>14 Day Patient Administration Kit<br>Rx only<br>Important: Dispense with prescription label positioned to remain with kit during use.<br>SUN PHARMA<br><img alt="leuprolide_outercarton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3b01473-30c7-4945-bd60-2484221aaaad&amp;name=leuprolide_outercarton.jpg"><br></span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LEUPROLIDE ACETATE 		
					</strong><br><span class="contentTableReg">leuprolide acetate kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:47335-936</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:47335-936-40</td>
<td class="formItem">1  in 1 CARTON; Combination Product Type = C102834</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, MULTI-DOSE </td>
<td class="formItem">2.8 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">28 PACKET </td>
<td class="formItem">28 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>LEUPROLIDE ACETATE 		
					</strong><br><span class="contentTableReg">leuprolide acetate injection, solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LEUPROLIDE ACETATE</strong> (LEUPROLIDE) </td>
<td class="formItem">LEUPROLIDE ACETATE</td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">6.3 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ACETIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2.8 mL in 1 VIAL, MULTI-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078885</td>
<td class="formItem">12/15/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>ISOPROPYL ALCOHOL 		
					</strong><br><span class="contentTableReg">isopropyl alcohol swab</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ISOPROPYL ALCOHOL</strong> (ISOPROPYL ALCOHOL) </td>
<td class="formItem">ISOPROPYL ALCOHOL</td>
<td class="formItem">0.7 mL  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 PACKET; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">OTC MONOGRAPH NOT FINAL</td>
<td class="formItem">part333A</td>
<td class="formItem">12/15/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078885</td>
<td class="formItem">12/15/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sun Pharma Global FZE
							(864347344)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sun Pharmaceutical Industries Limited</td>
<td class="formItem"></td>
<td class="formItem">725959238</td>
<td class="formItem">ANALYSIS(47335-936), MANUFACTURE(47335-936)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9e2cf202-7ee2-4f5b-9d21-dede139b7c5f</div>
<div>Set id: a3b01473-30c7-4945-bd60-2484221aaaad</div>
<div>Version: 5</div>
<div>Effective Time: 20150818</div>
</div>
</div> <div class="DistributorName">Sun Pharma Global FZE</div></p>
</body></html>
